Treatment of Keratoconus Using Collagen Cross-Linking
| Status: | Completed |
|---|---|
| Conditions: | Ocular, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Ophthalmology |
| Healthy: | No |
| Age Range: | 16 - 35 |
| Updated: | 4/2/2016 |
| Start Date: | September 2008 |
| End Date: | December 2011 |
| Contact: | James J. Reidy, M.D. |
| Email: | jreidymd@mac.com |
| Phone: | 716-881-7920 |
Treatment of Keratoconus Using Collagen Cross-Linking By Means of Topical Riboflavin and UV Light.
The purpose of this study is to determine the effectiveness of collagen cross-linking in the
cornea in halting the progression and possibly partially reversing the effects of
keratoconus. Keratoconus is a progressive weakening in the cornea that causes irregular
astigmatism and thinning of the cornea. The overall effect is reduction of vision, and in
more advanced cases, scarring of the cornea that may lead to the need for corneal
transplantation. Cross-linking has been shown increase the rigidity of the cornea. The
patients would be treated once and then followed over 24 months. .
cornea in halting the progression and possibly partially reversing the effects of
keratoconus. Keratoconus is a progressive weakening in the cornea that causes irregular
astigmatism and thinning of the cornea. The overall effect is reduction of vision, and in
more advanced cases, scarring of the cornea that may lead to the need for corneal
transplantation. Cross-linking has been shown increase the rigidity of the cornea. The
patients would be treated once and then followed over 24 months. .
The goal is for two groups of approximately 66 patients to be included in the study. One eye
from the first group will undergo treatment, while the second group of age matched
individuals will serve as a control. It will be a prospective, randomized, blinded study.
Each patient will be randomized at the beginning of enrollment in the study and will receive
a randomization number. The following parameters will be followed: 1. Best corrected
spectacle acuity (BCSA) 2. The steepest keratometry measurement (KMax) as measured by
computerized corneal topography 3. Apical corneal thickness 4. Corneal mechanical
resistance. These measurements will be repeated at 1 month, 3 months, 6 months, 12, 18, and
24 months following treatment.
from the first group will undergo treatment, while the second group of age matched
individuals will serve as a control. It will be a prospective, randomized, blinded study.
Each patient will be randomized at the beginning of enrollment in the study and will receive
a randomization number. The following parameters will be followed: 1. Best corrected
spectacle acuity (BCSA) 2. The steepest keratometry measurement (KMax) as measured by
computerized corneal topography 3. Apical corneal thickness 4. Corneal mechanical
resistance. These measurements will be repeated at 1 month, 3 months, 6 months, 12, 18, and
24 months following treatment.
Inclusion Criteria:
- no prior history of ocular surgery
- treatment eye must have a maximum corneal power of between 47 D and 60 diopters
- corneal thickness must be greater than 400 µ
- absence of corneal scarring
- patients must meet the diagnostic criteria for keratoconus, which include one or more
of the following features:
- high myopia
- corneal ectasia as viewed by slit-lamp exam or measured by pachometry
- Vogt's striae
- topographic findings of superior flattening and inferior steepening of the
cornea
- presence of Fleischer ring
Exclusion Criteria:
- history of prior ocular surgery (history of contact lens use is not an exclusion
criterion)
- average corneal power > 60 D
- presence of corneal scarring
- corneal thickness 400 µ or less
- history of herpes simplex virus keratitis
- history of uveitis
- pre-existing glaucoma
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials